Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.51 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15048924 | 0.87 | NPC1 (0.73) | NPC1EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22445036 | 0.82 | NPC1 (1.00) | NPC1EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL421042 | 0.79 | NPC1 (0.62) | NPC1EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22452619 | 0.78 | NPC1 (0.61) | NPC1EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL21551680 | 0.77 | NPC1 (0.49) | NPC1EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22453210 | 0.76 | NPC1 (0.59) | NPC1EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22453447 | 0.76 | NPC1 (0.59) | NPC1EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL419525 | 0.76 | SERPINE1 (0.74) | NPC1EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22453003 | 0.76 | NPC1 (0.58) | NPC1EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22452802 | 0.76 | NPC1 (0.58) | NPC1EPHX2LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | NPC1 893/4885EPHX2 2172/4885LMNA 482/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | NPC1 893/4885EPHX2 2172/4885LMNA 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.